Content about Aminoglycoside antibiotics

March 25, 2013
FDA approves Novartis antibacterial treatment for cystic fibrosis

The Food and Drug Administration has approved a treatment for managing a type of bacterial infection in patients with cystic fibrosis.

EAST HANOVER, N.J. — The Food and Drug Administration has approved a treatment for managing a type of bacterial infection in patients with cystic fibrosis.

Swiss drug maker Novartis announced the approval of Tobi Podhaler (tobramycin inhalation powder) for managing cystic fibrosis patients with Pseudomonas aeruginosa, or Pa bacteria, in the lungs.

September 6, 2012
FDA advisory committee recommends approval for Novartis cystic fibrosis drug

A panel of Food and Drug Administration experts is recommending that the agency approve an experimental drug for cystic fibrosis made by Novartis, the Swiss drug maker said.

EAST HANOVER, N.J. — A panel of Food and Drug Administration experts is recommending that the agency approve an experimental drug for cystic fibrosis made by Novartis, the Swiss drug maker said.

October 17, 2010
Fera launches Garamycin

Fera Pharmaceuticals has launched a preservative-free ointment for treating bacterial infections of the eye, the...

NEW YORK Fera Pharmaceuticals has launched a preservative-free ointment for treating bacterial infections of the eye, the company said Monday.

 

Fera said the launch of Garamycin (gentamicin sulfate) was to meet an unmet need for a preservative-free version of the drug. The Food and Drug Administration had received reports of allergic reactions in infants who had received formulations of the drug with preservatives.